Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis

Objective To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine. Design Economic evaluation using a cohort model from the perspective of healthcare providers. Setting England. Partic...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozenbaum, Mark H, van Hoek, Albert Jan, Fleming, Douglas, Trotter, Caroline L, Miller, Elizabeth, Edmunds, W John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482156/
https://www.ncbi.nlm.nih.gov/pubmed/23103369
http://dx.doi.org/10.1136/bmj.e6879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482156/
https://www.ncbi.nlm.nih.gov/pubmed/23103369
http://dx.doi.org/10.1136/bmj.e6879

Ejemplares similares